Physician

Daniel Nathaniel Efiom-Ekaha, MD

According to 2025 Medicare claims, Daniel Efiom-Ekaha, MD (NPI: 1396783122) practices hematology/oncology in the York-Hanover, PA market, with the plurality of this provider's patient population coming from York, PA. This provider's primary affiliated billing organization is CANCER CARE ASSOCIATES OF YORK, INC. (NPI: 1578587101; TIN: 232122436) and primary practice location at 17403-5049.

Efiom-Ekaha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 745 traditional Medicare patients, billed 138,135 HCPCS/CPT codes, and received $2,965,064 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,150 prescription claims across 226 beneficiaries totaling $1,494,632 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). 2022 DME data shows 12 claims. Open Payments data shows 75 records totaling $64,940. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $719,797 to $1,494,632. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,298 and ending at $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	789	171,911	$1,875,756
2016	794	166,478	$1,931,330
2017	845	172,938	$2,127,628
2018	827	168,650	$2,353,218
2019	848	165,819	$2,662,338
2020	846	168,981	$2,290,911
2021	925	130,580	$2,285,536
2022	798	125,013	$1,946,020
2023	778	130,332	$2,139,084
2024	745	138,135	$2,965,064

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	240	1,127	$719,797
2016	237	1,085	$472,902
2017	243	1,059	$354,550
2018	237	1,052	$425,376
2019	242	1,013	$244,183
2020	177	876	$492,087
2021	182	911	$574,422
2022	177	805	$841,034
2023	194	941	$1,897,365
2024	226	1,150	$1,494,632

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	45	146	$48,801
2016	53	121	$26,320
2017	72	185	$15,335
2018	90	149	$5,646
2019	N/R	25	$3,153
2020	N/R	N/R	N/R
2021	N/R	25	$3,649
2022	N/R	12	$366
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	267	619	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	166	224	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	304	603	$12
36415	Insertion of needle into vein for collection of blood sample	331	1,334	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	293	1,215	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	34	1,020	$66,618
Eliquis	Apixaban	42	1,368	$26,538
Enoxaparin Sodium	Enoxaparin Sodium	36	1,042	$14,547
Exemestane	Exemestane	57	3,390	$9,930
Anastrozole	Anastrozole	198	14,700	$3,631

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	70	$56,790	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$8,150	ARRAY BIOPHARMA INC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Nathaniel Efiom-Ekaha, MD?

Tedicare shows public-source Medicare data for Daniel Nathaniel Efiom-Ekaha, MD (NPI 1396783122), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Nathaniel Efiom-Ekaha, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Nathaniel Efiom-Ekaha, MD?

Daniel Nathaniel Efiom-Ekaha, MD is linked to CANCER CARE ASSOCIATES OF YORK, INC. (billing NPI 1578587101) in the available physician profile data.

Does Daniel Nathaniel Efiom-Ekaha, MD have Open Payments data?

Daniel Nathaniel Efiom-Ekaha, MD has 75 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.